Pharma’s Almanac Magazine

Advances in our understanding of enzymatic transformations and the increased availability of enzymes engineered for use in fine chemical synthesis is making biocatalysis attractive for the production of chiral pharmaceutical intermediates and APIs. Seqensis leveraging its expertise in chemo- and biocatalysis to identify cost-effective routes to increasingly complex small molecule drug substances with chiral centers.